<DOC>
	<DOCNO>NCT00294320</DOCNO>
	<brief_summary>The purpose study evaluate performance two technique monitor clearance AK lesion treat Aldara 5 % cream .</brief_summary>
	<brief_title>Evaluation Two Different Non-Invasive Techniques Monitor Clearance Actinic Keratosis Lesions</brief_title>
	<detailed_description>Each technique assess comparison lesion count ( clinical sub-clinical ) reveal technique , start end study demonstrate treatment . In addition qualitative assessment technique make performance ease use .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>At least 5 clinically typical , visible , discrete , nonhyperkeratotic , nonhypertrophic AK lesion Free significant finding ( e.g tattoo ) potential application site area . Willing discontinue suntanning use sunbed/sun parlour use Willing stop use moisturisers , body oil , counter retinol product product contain alpha beta hydroxyacids treatment surround area . Willing ot withhold sunscreen and/or moisturiser use 24 hour prior clinical assessment Evidence unstable uncontrolled clinically significant medical condition . Any dermatological disease condition treatment surround area may exacerbate treatment imiquimod . Currently participate another clinical study complete another study within investigational drug within past 30 day . Have active chemical dependency alcoholism Have know allergy excipient study cream Have receive previous treatment imiquimod indication within treatment area . Known affect porphyria</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>Aldara</keyword>
	<keyword>Actinic Keratosis</keyword>
</DOC>